Clinical Trials

13 results for Bladder Cancer


Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

  • Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01050504
View Trial

Familial and Atypical Urothelial Cancer Registry

  • Condition: Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
  • Intervention: Other: saliva sample and questionaire, Other: saliva sample, questionaire
  • Study ID: NCT00902590
View Trial

Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

  • Condition: Invasive Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Radiation: Radiotherapy
  • Study ID: NCT02560636
View Trial

A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum

  • Condition: Stage IV Bladder Urothelial Carcinoma
  • Intervention: Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Procedure: Positron Emission Tomography, Biological: Recombinant EphB4-HSA Fusion Protein
  • Study ID: NCT02717156
View Trial

A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab, Drug: Ipilimumab, Procedure: Radical cystectomy
  • Study ID: NCT03520491
View Trial

Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS")"

  • Condition: Upper Tract Urothelial Carcinoma
  • Intervention: Procedure: RNU, Drug: Gemcitabine/Cisplatin, Drug: M-VAC Protocol
  • Study ID: NCT02969083
View Trial

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

  • Condition: Urothelial Carcinoma
  • Study ID: NCT03547973
View Trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

  • Condition: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
  • Study ID: NCT03775265
View Trial

A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

  • Condition: Urinary Bladder Cancer, Invasive Bladder Cancer
  • Intervention: Combination Product: nivolumab 480mg, Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg, Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg
  • Study ID: NCT03844256
View Trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Co

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Atezolizumab, Drug: Enfortumab Vedotin, Drug: Niraparib, Drug: Hu5F9-G4, Drug: Isatuximab, Drug: Linagliptin, Drug: Tocilizumab
  • Study ID: NCT03869190
View Trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEY

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Pembrolizumab, Radiation: Conventional Radiotherapy (Bladder only), Radiation: Conventional Radiotherapy (Bladder and pelvic nodes), Radiation: Hypofractionated Radiotherapy (Bladder only), Drug: Cisplatin, Drug: Fluorouracil (5-FU), Drug: Mitomycin C (MMC), Drug: Gemcitabine, Drug: Placebo to Pembrolizumab
  • Study ID: NCT04241185
View Trial

Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

  • Condition: Bladder Cancer, Bladder Cancer, Metastatic
  • Intervention: Drug: Atezolizumab
  • Study ID: NCT04138628
View Trial

Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)

  • Condition: Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
  • Study ID: NCT04936230
View Trial